Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Tax Provisions: 2009-2024

Historic Tax Provisions for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $6.1 million.

  • Anika Therapeutics' Tax Provisions fell 57.32% to $939,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 66.33%. This contributed to the annual value of $6.1 million for FY2024, which is 8.05% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Tax Provisions is $6.1 million, which was down 8.05% from $6.6 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Tax Provisions ranged from a high of $6.6 million in FY2023 and a low of -$4.6 million during FY2020.
  • Moreover, its 3-year median value for Tax Provisions was $6.1 million (2024), whereas its average is $5.6 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first slumped by 151.99% in 2020, then soared by 346.34% in 2022.
  • Anika Therapeutics' Tax Provisions (Yearly) stood at -$4.6 million in 2020, then surged by 63.23% to -$1.7 million in 2021, then soared by 346.34% to $4.2 million in 2022, then spiked by 56.84% to $6.6 million in 2023, then declined by 8.05% to $6.1 million in 2024.